{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:38:19Z","timestamp":1771465099431,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1136\/annrheumdis-2012-202603","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T02:47:53Z","timestamp":1362624473000},"page":"198-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":303,"title":["Inequities in access to biologic and synthetic DMARDs across 46 European countries"],"prefix":"10.1016","volume":"73","author":[{"given":"Polina","family":"Putrik","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[]},{"given":"Tuulikki","family":"Sokka","sequence":"additional","affiliation":[]},{"given":"Milena","family":"Pavlova","sequence":"additional","affiliation":[]},{"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[]},{"given":"Argjent","family":"Tafaj","sequence":"additional","affiliation":[]},{"given":"Ruzanna","family":"Harutyunyan","sequence":"additional","affiliation":[]},{"given":"Helga","family":"Radner","sequence":"additional","affiliation":[]},{"given":"Nikolay","family":"Soroka","sequence":"additional","affiliation":[]},{"given":"Herman","family":"Mielants","sequence":"additional","affiliation":[]},{"given":"Sekib","family":"Sokolovic","sequence":"additional","affiliation":[]},{"given":"Sevdalina","family":"Lambova","sequence":"additional","affiliation":[]},{"given":"Miroslav","family":"Mayer","sequence":"additional","affiliation":[]},{"given":"Paraskevi","family":"Charalambous","sequence":"additional","affiliation":[]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[]},{"given":"T\u00f5nu","family":"Peets","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[]},{"given":"Khatuna","family":"Letsveridze","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[]},{"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[]},{"given":"Gerdur","family":"Gr\u00f6ndal","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[]},{"given":"Seriolo","family":"Bruno","sequence":"additional","affiliation":[]},{"given":"Galimzhan","family":"Togizbayev","sequence":"additional","affiliation":[]},{"given":"Daina","family":"Andersone","sequence":"additional","affiliation":[]},{"given":"Irena","family":"Butrimien\u0117","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Hirsch","sequence":"additional","affiliation":[]},{"given":"Snezana","family":"Misevska-Percinkova","sequence":"additional","affiliation":[]},{"given":"Karen","family":"Cassar","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Deseatnicova","sequence":"additional","affiliation":[]},{"given":"Dusan","family":"Mustur","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"G\u0142uszko","sequence":"additional","affiliation":[]},{"given":"Viviana","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Florian","family":"Berghea","sequence":"additional","affiliation":[]},{"given":"Ivan","family":"Shirinsky","sequence":"additional","affiliation":[]},{"given":"Miodrag","family":"Veljkovic","sequence":"additional","affiliation":[]},{"given":"Jozef","family":"Rovensky","sequence":"additional","affiliation":[]},{"given":"Matija","family":"Tomsic","sequence":"additional","affiliation":[]},{"given":"Francisca","family":"Sivera","sequence":"additional","affiliation":[]},{"given":"Ingemar F.","family":"Petersson","sequence":"additional","affiliation":[]},{"given":"Finckh","family":"Axel","sequence":"additional","affiliation":[]},{"given":"Sharipov","family":"Shaydullo","sequence":"additional","affiliation":[]},{"given":"Nevsun","family":"Inanc","sequence":"additional","affiliation":[]},{"given":"Tatyana","family":"Dumenko","sequence":"additional","affiliation":[]},{"given":"Suzanne","family":"Verstappen","sequence":"additional","affiliation":[]},{"given":"Hojimurad","family":"Khudoberdiev","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2012-202603_bib1","unstructured":"Tien geneesmiddelen, 20% van de uitgaven Stichting Farmaceutische Kengetallen (Foundation for Pharmaceutical Statistics); [cited 30 May 2012]; http:\/\/www.sfk.nl\/."},{"issue":"Suppl 2","key":"10.1136\/annrheumdis-2012-202603_bib2","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/s10198-007-0087-9","article-title":"The burden of rheumatoid arthritis and access to treatment: a medical overview","volume":"8","author":"Smolen","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1136\/annrheumdis-2012-202603_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1136\/annrheumdis-2012-202603_bib4","unstructured":"Kobelt G, Kasteng F,. Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Phaumeceutical industry associations (EFPIA), 2009."},{"key":"10.1136\/annrheumdis-2012-202603_bib5","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/ard.2009.109983","article-title":"Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST RA database","volume":"68","author":"Sokka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202603_bib6","series-title":"Investment for health: a discussion of the role of economic and social determinants.","author":"World Health Organization (WHO)","year":"2002"},{"key":"10.1136\/annrheumdis-2012-202603_bib7","unstructured":"WHO. HIA Glossary of Terms. 2012. [cited July 2012]; http:\/\/www.who.int\/hia\/about\/en\/."},{"key":"10.1136\/annrheumdis-2012-202603_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S1744133109990144","article-title":"Access and choice\u2014competition under the roof of solidarity in German health care: an analysis of health policy reforms since 2004","volume":"5","author":"Lisac","year":"2010","journal-title":"Health Econ Policy Law"},{"key":"10.1136\/annrheumdis-2012-202603_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1258\/135581902760082517","article-title":"What does \u2018access to health care\u2019 mean?","volume":"7","author":"Gulliford","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1136\/annrheumdis-2012-202603_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1756-0500-3-340","article-title":"Illness costs to households are a key barrier to access diagnostic and treatment services for tuberculosis in Tajikistan","volume":"3","author":"Ay\u00e9","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1136\/annrheumdis-2012-202603_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S1744133109004836","article-title":"Access as a policy-relevant concept in low- and middle-income countries","volume":"4","author":"McIntyre","year":"2009","journal-title":"Health Econ Policy Law"},{"key":"10.1136\/annrheumdis-2012-202603_bib12","unstructured":"WHO Regional Office for Europe. [cited 20 Oct 2011]; http:\/\/www.euro.who.int\/en\/home."},{"key":"10.1136\/annrheumdis-2012-202603_bib13","unstructured":"The European Musculoskeletal Conditions Surveillance and Information Network (eumusc.net). [cited 15 Jan 2012]; http:\/\/eumusc.net\/."},{"key":"10.1136\/annrheumdis-2012-202603_bib14","unstructured":"The World Bank. [cited 2011 October 26th]; http:\/\/www.worldbank.org\/."},{"key":"10.1136\/annrheumdis-2012-202603_bib15","unstructured":"European health for all database (HFA-DB). [cited 26 Oct 2011]; http:\/\/data.euro.who.int\/hfadb\/."},{"key":"10.1136\/annrheumdis-2012-202603_bib16","unstructured":"European Comission (EUROSTAT). [cited 26 Oct 2011]; http:\/\/epp.eurostat.ec.europa.eu\/portal\/page\/portal\/eurostat\/home\/."},{"key":"10.1136\/annrheumdis-2012-202603_bib17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202603_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202603_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202603_bib20","doi-asserted-by":"crossref","first-page":"SR1","DOI":"10.12659\/MSM.881697","article-title":"Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries","volume":"17","author":"Orlewska","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1136\/annrheumdis-2012-202603_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/radiol.2273011499","article-title":"Correlation and simple linear regression","volume":"227","author":"Zou","year":"2003","journal-title":"Radiology"},{"key":"10.1136\/annrheumdis-2012-202603_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.healthpol.2011.10.011","article-title":"Do rheumatoid arthritis patients have equal access to treatment with new medicines? tumour necrosis factor-alpha inhibitors use in four European countries","volume":"104","author":"Hoebert","year":"2012","journal-title":"Health Policy"},{"key":"10.1136\/annrheumdis-2012-202603_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semarthrit.2010.09.004","article-title":"Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy","volume":"41","author":"Pease","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202603_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/acr.20338","article-title":"Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review","volume":"63","author":"van der Velde","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2012-202603_bib25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jval.2011.05.004","article-title":"Patient access to new cancer drugs in the United States and Australia","volume":"14","author":"Wilson","year":"2011","journal-title":"Value Health"},{"key":"10.1136\/annrheumdis-2012-202603_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-8462-4-2","article-title":"The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines","volume":"4","author":"Lu","year":"2007","journal-title":"Aust New Zealand Health Policy"},{"key":"10.1136\/annrheumdis-2012-202603_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/03009742.2010.493895","article-title":"Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009","volume":"40","author":"Neovius","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/annrheumdis-2012-202603_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.berh.2012.07.011","article-title":"Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA","volume":"26","author":"Putrik","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724212413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724212413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2012-202603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:43:41Z","timestamp":1737351821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724212413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0003496724212413"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}